Clinical Trial Update: 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of 5-Azacytidine and/or Nivolumab in patients with resectable HPV-associated head and neck squamous cell carci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• 5-Azacytidine (5-azacytidine)
• nivolumab (nivolumab)

Snippet

Sponsor: Barbara Burtness | Conditions: Squamous Cell Carcinoma of Head and Neck | Phase 2 | Status: RECRUITING